)
)
Galecto Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Galecto Inc
Access all reports
Galecto Inc. is a clinical-stage biotechnology company primarily focused on the development of small molecule therapeutics aimed at critical aspects of cancer and fibrotic diseases. Their research and development efforts are centered around the inhibition of galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins that play a pivotal role in the progression of these conditions. Galecto's portfolio includes GB0139, designed for treating Idiopathic Pulmonary Fibrosis (IPF), a serious progressive fibrotic lung disease; GB1211, a selective oral small molecule inhibitor of galectin-3 for various oncology indications and liver cirrhosis; and GB2064, targeting LOXL2 for the treatment of myelofibrosis. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
GLTO
Country
🇺🇸 United States